192 related articles for article (PubMed ID: 32859533)
1. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
2. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Lyons TJ; Goodall RJ; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684686
[TBL] [Abstract][Full Text] [Related]
6. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
[TBL] [Abstract][Full Text] [Related]
8. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.
Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE
Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580
[TBL] [Abstract][Full Text] [Related]
9. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
[TBL] [Abstract][Full Text] [Related]
10. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
[TBL] [Abstract][Full Text] [Related]
11. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
[TBL] [Abstract][Full Text] [Related]
12. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
13. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Provencher DM; Gallagher CJ; Parulekar WR; Ledermann JA; Armstrong DK; Brundage M; Gourley C; Romero I; Gonzalez-Martin A; Feeney M; Bessette P; Hall M; Weberpals JI; Hall G; Lau SK; Gauthier P; Fung-Kee-Fung M; Eisenhauer EA; Winch C; Tu D; MacKay HJ
Ann Oncol; 2018 Feb; 29(2):431-438. PubMed ID: 29186319
[TBL] [Abstract][Full Text] [Related]
14. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
Jorgensen K; Melamed A; Wu CF; Nitecki R; Pareja R; Fagotti A; Schorge JO; Ramirez PT; Rauh-Hain JA
Gynecol Oncol; 2023 May; 172():130-137. PubMed ID: 36977622
[TBL] [Abstract][Full Text] [Related]
15. Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival.
Coada CA; Dondi G; Ravegnini G; Di Costanzo S; Tesei M; Fiuzzi E; Di Stanislao M; Giunchi S; Zamagni C; Bovicelli A; Hrelia P; Angelini S; De Iaco P; Perrone AM
J Gynecol Oncol; 2023 Nov; 34(6):e82. PubMed ID: 37743060
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
Fleming ND; Westin SN; Rauh-Hain JA; Soliman PT; Fellman BM; Coleman RL; Meyer LA; Shafer A; Cobb LP; Jazaeri A; Lu KH; Sood AK
Gynecol Oncol; 2021 Jul; 162(1):65-71. PubMed ID: 33838925
[TBL] [Abstract][Full Text] [Related]
18. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of epithelial ovarian cancer treated at a tertiary-level hospital in India.
Chandy RG; Thomas V; Sebastian A; Mani T; Thomas A; Joel A; Ram TS; Peedicayil A
Indian J Cancer; 2023 Oct; 60(4):475-485. PubMed ID: 38185864
[TBL] [Abstract][Full Text] [Related]
20. Neo-adjuvant chemotherapy does not reduce surgical complexity nor the accuracy of intra-operative visual assessment of disease in advanced ovarian cancer.
Addley S; McGowan M; Crossland H; Johnson A; Asher V; Bali A; Abdul S; Phillips A
Eur J Surg Oncol; 2023 Nov; 49(11):107078. PubMed ID: 37804584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]